Key result
Higher plasma ADMA linked to ~37% greater risk of major events in stage 3-4 CKD.
Why the study?
Elevated plasma ADMA levels have been associated with endothelial dysfunction and cardiovascular risk in ESRD, but their association with long-term outcomes in stage 3 to 4 CKD patients was unclear.
Does elevated plasma ADMA level predict composite outcomes of all-cause death, nonfatal MI, and stroke in patients with stage 3 to 4 CKD?
Population
298 consecutive patients with stage 3 to 4 CKD scheduled for coronary angiography
Comparison
Plasma ADMA levels
Design
Cohort study
Follow-up
Median 2.7 years
Authors
Loading...
ADMA may stratify CV risk in stage 3-4 CKD; leaves open whether it is a modifiable target or aids decision-making.
Cohort (n=298)
Does elevated plasma ADMA level predict composite outcomes of all-cause death, nonfatal MI, and stroke in patients with stage 3 to 4 CKD?
Hazard Ratio: 1.37
Elevated plasma ADMA levels serve as an independent predictor of long-term adverse cardiovascular outcomes and mortality in elderly, high-risk patients with stage 3 to 4 CKD.
Lu et al. (2011) conducted a cohort in Stage 3 to 4 chronic kidney disease (CKD) (n=298). Plasma asymmetric dimethylarginine (ADMA) vs. Lower ADMA levels was evaluated on Composite of all-cause deaths, nonfatal myocardial infarctions, and strokes (37% increased risk per 0.1 μmol/L increase). In patients with stage 3 to 4 CKD, a 0.1 μmol/L increase in plasma ADMA level was associated with a 37% increased risk of all-cause death, nonfatal MI, and stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: